🇺🇸 Indacaterol/glycopyrronium in United States

25 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 25

Most-reported reactions

1. Drug Interaction — 5 reports (20%)
2. Sars-Cov-2 Sepsis — 5 reports (20%)
3. Tubulointerstitial Nephritis — 4 reports (16%)
4. Acute Kidney Injury — 2 reports (8%)
5. Epistaxis — 2 reports (8%)
6. International Normalised Ratio Increased — 2 reports (8%)
7. Sterile Pyuria — 2 reports (8%)
8. Blood Creatinine Increased — 1 report (4%)
9. Cholestatic Liver Injury — 1 report (4%)
10. Covid-19 Pneumonia — 1 report (4%)

Source database →

Frequently asked questions

Is Indacaterol/glycopyrronium approved in United States?

Indacaterol/glycopyrronium does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Indacaterol/glycopyrronium in United States?

Orion Corporation, Orion Pharma is the originator. The local marketing authorisation holder may differ — check the official source linked above.